Hydrocortisone Butyrate

CHEMBL1683 Phase 4 Approuvé Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
432.5 g/mol
LogP
3.2
Phase
4

A butyrate ester of hydrocortisone with greater lipophilicity than the parent compound, used as a moderate-potency topical corticosteroid for inflammatory skin conditions such as atopic dermatitis and psoriasis. This formulation penetrates the skin effectively to deliver anti-inflammatory activity with relatively lower systemic absorption. It is available in cream and ointment formulations for external use.

Masse moléculaire

432,5000 g/mol

LogP

3,20

TPSA

101,00 Ų

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Mécanisme d'action

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Structure 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCCC(=O)O[C@]1(C(=O)CO)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C

InChI

InChI=1S/C25H36O6/c1-4-5-21(30)31-25(20(29)14-26)11-9-18-17-7-6-15-12-16(27)8-10-23(15,2)22(17)19(28)13-24(18,25)3/h12,17-19,22,26,28H,4-11,13-14H2,1-3H3/t17-,18-,19-,22+,23-,24-,25-/m0/s1

Molecular Formula

C25H36O6

HBD / HBA

2 / 6

Liaisons Rotatives

6

Atomes Lourds

31

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

A butyrate ester of hydrocortisone with greater lipophilicity than the parent compound, used as a moderate-potency topical corticosteroid for inflammatory skin conditions such as atopic dermatitis and psoriasis. This formulation penetrates the skin effectively to deliver anti-inflammatory activity with relatively lower systemic absorption. It is available in cream and ointment formulations for external use.

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Yes, Hydrocortisone Butyrate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1683. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 26133. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.